In this article
Libtayo FDA Approval for Advanced NSCLC
November 2022: The combination of cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) and platinum-based chemotherapy for adult patients with advanced non-small cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 abnormalities has been approved by the Food and Drug Administration.
Study 16113 (NCT03409614), a randomised, multicenter, international, double-blind, active-controlled trial in 466 patients with advanced NSCLC who had not previously undergone systemic treatment, assessed the effectiveness in this regard. Cemiplimab-rwlc plus platinum-based chemotherapy every 3 weeks for 4 cycles, followed by cemiplimab-rwlc and maintenance chemotherapy, or placebo plus platinum-based chemotherapy every 3 weeks for 4 cycles, followed by placebo and maintenance chemotherapy, were the two treatment options offered to patients who were randomly assigned (2:1).
Significant Improvements in Overall Survival and PFS
Overall survival was the primary efficacy outcome measurement (OS). Progression-free survival (PFS) and overall response rate (ORR), as determined by a blinded independent central review, were additional efficacy outcome measures (BICR).
In comparison to placebo plus chemotherapy, cemiplimab-rwlc plus platinum-based chemotherapy showed a statistically significant and clinically significant improvement in overall survival (OS) (hazard ratio [HR] of 0.71 [95% CI: 0.53, 0.93], two-sided p-value = 0.0140). In the cemiplimab-rwlc plus chemotherapy arm, the median OS was 21.9 months (95% CI: 15.5, not evaluable), compared to 13.0 months (95% CI: 11.9, 16.1) in the placebo plus chemotherapy group. In the cemiplimab-rwlc plus chemotherapy arm, the median PFS per BICR was 8.2 months (95% CI: 6.4, 9.3), while it was 5.0 months (95% CI: 4.3, 6.2) in the placebo plus chemotherapy arm (HR 0.56; 95% CI: 0.44, 0.70, p0.0001). Confirmed ORR per BICR for the two treatments was 43% (95% CI: 38, 49) and 23% (95% CI: 16, 30).
Libtayo Side Effects and Dosage Guidelines
Alopecia, musculoskeletal pain, nausea, exhaustion, peripheral neuropathy, and decreased appetite were the most frequent side effects (15%).
350 mg IV every three weeks is the suggested dose of cemiplimab-rwlc. For recommended dose information, as necessary, see the prescribing information for the medications used in conjunction with cemiplimab-rwlc.
View full prescribing information for Libtayo
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.